• Français

Centre de recherche
Tuesday, April 30 2019
Press release

A promising new treatment for infants with Noonan Syndrome

MONTRÉAL, April 30, 2019 – Noonan Syndrome (NS) is a rare genetic syndrome typically evident at birth and often linked to early-onset severe heart disease. NS is part of a group of diseases termed RASopathies that are caused by activating mutations of proteins belonging to the Ras and mitogen-activated protein kinase families.

In a new study, researchers at Université de Montréal and CHU Sainte-Justine Research Center show that a MEK inhibitor called trametinib can reverse hypertrophic cardiomyopathy (HCM) and valvular obstruction in patients with RIT1-associated NS. The groundbreaking research is published in the Journal of the American College of Cardiology.

‘’Up to this finding, our therapeutic options were limited to surgery, including heart transplant, and symptomatic relief with medication,” said the study’s author, Dr. Gregor Andelfinger, a pediatric cardiologist at CHU Sainte-Justine, a researcher at Sainte-Justine University Hospital Research Center in the fetomaternal and neonatal pathologies axis, and an associate research professor in the pediatrics department of Université de Montréal.

“Trametinib treatment is the first approach specifically targeted to the molecular cause of RASopathies,” said Dr. Andelfinger. “While our numbers are still very limited, we report the first patients in whom we were not only able to stabilize, but to reverse the disease of the heart. These results pave the way for larger trials, which are now needed.”

Dramatic improvement

Infants less than six months old with NS, HCM and congestive heart failure normally have a poor prognosis, with a one-year survival rate of 34 per cent. In the new study, the Sainte Justine clinical teams used trametinib, an inhibitor targeted specifically against the activating nature of the mutations, to try to treat NS in two patients.

They observed dramatic improvement of clinical and cardiac status in the patients only three months after treatment. Hypertrophy regressed in both patients, with sustained improvement over a total of 17 months of treatment, and normalization of laboratory values. One of the patients, who required ventilation, could be extubated after six weeks of treatment. Both patients showed better overall growth after treatment was started.

"The findings described in this report suggest that a life-threatening form of heart disease affecting young infants might be treatable, which, if true, would be unprecedented and so meaningful for the families whose lives this devastating problem touches,” commented Dr. Bruce Gelb, director of the Mindich Child Health and Development Institute at the Icahn School of Medicine at Mount Sinai,  in New York City.

“Now we need to perform a proper clinical trial to prove that this drug is definitely working for this particular problem," he said.

A promising first

Although the study was limited to two patients, given the promising results these outcomes suggest that MEK inhibition merits further study as a mechanistic treatment option for patients with RASopathies, the researchers believe. The study raises important questions for the treatment of such cases, in particular with respect to long-term efficacy and impact on other RASopathy manifestations.

Because of the role MEK plays in signaling heart growth, Gregor Andelfinger believes studies with a larger number of participants are now required to evaluate long-term side effects, optimal dosing and optimal treatment windows as well as investigate this treatment for other types of heart disease.  It is conceivable that MEK inhibition may prove most effective during a fixed time window before the onset of irreversible cardiac remodeling in RASopathies, including those caused by genes other than RIT1.


About the study

Dr. Gregor Andelfinger is a pediatric cardiologist at CHU Sainte-Justine, a researcher at CHU Sainte-Justine Research Center in the Fetomaternal and Neonatal Pathologies axis, and Associate Professor in the Department of Pediatrics at Université de Montréal. He also holds the National Bank Research Excellence Chair in Cardiovascular Genetics. This work was made possible through the collaboration of researchers in many specialties and departments at Sainte-Justine, including pharmacy, hemato-oncology and genetics. The study was funded by the Fonds de Recherche du Québec – Santé and the National Bank Research Excellence Chair in Cardiovascular Genetics. The study also received support from the German Federal Ministry of Education and Research (BMBF): NSEuroNet (FKZ 01GM1602A), GeNeRARe (FKZ 01GM1519A). Dr. Bruce Gelb received support from the U.S. National Heart, Lung and Blood Institute (HL135742).

– 30 –

About the CHU Sainte-Justine Research Center

The CHU Sainte-Justine Research Center is a leading mother-child research institution affiliated with Université de Montréal. It brings together more than 200 research investigators, including over 90 clinician-scientists, as well as 500 graduate and postgraduate students focused on finding innovative prevention means, faster and less invasive treatments, as well as personalized approaches to medicine. The Center is part of CHU Sainte-Justine, which is the largest mother-child center in Canada and one of the four most important pediatric centres in North America. More on research.chusj.org

About CHU Sainte-Justine

Sainte-Justine University Hospital Centre is the largest mother-child hospital in Canada. It is a member of Université de Montréal's extended excellence-in-health network (RUIS). Sainte-Justine has 5,457 employees, including 1,532 nurses and nursing assistants; 1,000 other healthcare professionals; 520 physicians, dentists and pharmacists; 822 residents and over 204 researchers; 411 volunteers; and 4,416 interns and students in a wide range of disciplines. CHU Sainte-Justine has 484 beds, including 67 at the Centre de réadaptation Marie Enfant (CRME), the only exclusively pediatric rehabilitation centre in Quebec. The World Health Organization has recognized CHU Sainte-Justine as a "health promoting hospital."

Source
CHU Sainte-Justine
Contact

Communications, CHU Sainte-Justine Research Center
communications@recherche-ste-justine.qc.ca

Media contact:

Florence Meney
Executive advisor – External communications
CHU Sainte-Justine
Office: 514-345-7707
Cell.: 514-755-2516
florence.meney.hsj@ssss.gouv.qc.ca

 

Persons mentioned in the text
About this page
Updated on 4/29/2019
Created on 4/29/2019
Alert or send a suggestion
 

Every dollar counts!

Thank you for your generosity.

It's people like you that allow us to accelerate research and heal more children better every year and, as such, offer among the best healthcare in the world.

It's also possible to give by mail or by calling toll-free

1-888-235-DONS (3667)

Contact Us

514 345-4931

Légal

© 2006-2014 CHU Sainte-Justine.
All rights reserved.
Terms of Use, Confidentiality, Security

Avertissement

Les informations contenues dans le site « CHU Sainte-Justine » ne doivent pas être utilisées comme un substitut aux conseils d’un médecin dûment qualifié et autorisé ou d’un autre professionnel de la santé. Les informations fournies ici le sont à des fins exclusivement éducatives et informatives.

Consultez votre médecin si vous croyez être malade ou composez le 911 pour toute urgence médicale.

CHU Sainte-Justine